Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Baxter International Inc.    BAX   US0718131099

SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

Baxter International Inc. : Baxter's Investigational Hemophilia Treatment Yields Positive Results

12/10/2012 | 09:34am US/Eastern
Recommend:
0
    By Saabira Chaudhuri 
 

Baxter International Inc. (BAX) said results from a study evaluating its investigational treatment for patients with hemophilia B were positive.

The medical product company's BAX 326--its investigational recombinant factor IX protein for the treatment and prophylaxis of bleeding episodes for patients with hemophilia B over 12 years of age--was recently granted orphan-drug designation by the U.S. Food and Drug Administration.

"With only one recombinant protein currently available to treat hemophilia B, it was important to focus research efforts on finding another option for patients with this debilitating disease," Lead Investigator Jerzy Windyga said. "In this study, more than 40 percent of patients using BAX 326 as a prophylactic treatment experienced no bleeds, an important finding given the potentially harmful impact of bleeding episodes for patients."

The study investigated the efficacy and safety of BAX 326 in 73 previously treated patients with severe or moderately severe hemophilia B.

Baxter noted that hemophilia B is the second most common type of hemophilia--also known as Christmas disease--and is the result of insufficient amounts of clotting factor IX, a naturally occurring protein in blood that controls bleeding. The company added that about 25,000 people world-wide, including more than 4,000 in the U.S., have been diagnosed with hemophilia B.

Baxter's profits have improved for more than a year on strong demand for its hemophilia and immunodeficiency products. Its bottom line has been less pressured by the slowdown in health-care spending, compared with some peers, because Baxter focuses on medical devices and pharmaceuticals used to treat life-threatening ailments and injuries.

In October, Baxter said its third-quarter earnings rose 1.2% as the company's margins improved, though sales were short of its prior guidance.

Shares closed Friday at $65.07 and were inactive in recent premarket trading. The stock has risen 32% so far this year.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Recommend :
0
React to this article
Latest news on BAXTER INTERNATIONAL INC.
11h ago BAXTER : FDA Approves Baxter's RIXUBIS for Treatment of Children with Hemophilia..
13h ago BAXTER : FDA Approves Baxter’s HYQVIA for Treatment of Adults with Primary..
13h ago BAXTER : FDA Approves Baxter’s RIXUBIS for Treatment of Children with Hemo..
15h ago BAXTER : Assigned Patent
3d ago BAXTER : FDA Approves Baxter’s HYQVIA for Treatment of Adults with Primary..
3d ago BAXTER : Announces Baxalta as the Name of the New Global Biopharmaceutical Compa..
4d ago BAXTER : Announces Baxalta as the Name of New Global Biopharmaceutical Company
5d agoDJBaxter Spinoff Drug Business to Be Named Baxalta
5d agoDJBaxter Spinoff Drug Business to Be Named Baxalta
5d ago BAXTER : Announces Baxalta as the Name of New Global Biopharmaceutical Company
Advertisement
Chart
Duration : Period :
Baxter International Inc. Technical Analysis Chart | BAX | US0718131099 | 4-Traders
Income Statement Evolution
Baxter International Inc. : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF